M.A. Berciano-Guerrero, A. Montesa-Pino, G. Castaneda-Penalvo, L. Munoz-Fernandez and J. Rodriguez-Flores Pages 3701 - 3716 ( 16 )
Malignant melanoma is one of the most common causes of cancer and cancer deaths in young people. Until few years ago, scarce drugs have proven efficacy in metastatic setting. However, in the recent years, the treatment of metastatic malignant melanoma has undergone the incorporation of effective treatment such as immunotherapy, the use of tyrosine kinase inhibitors and the emergence of other cytostatic compounds, like the nanoparticles. This review aims to propose a standardization to classify the different types of nanoparticles, according to chemical aspects, and update the clinical research with nanoparticles and their use in melanoma field.
Cancer, classification, melanoma, nab-paclitaxel, nanoparticles.
, , , , Medical Oncology Section, Hospital Regional Universitario Carlos Haya, Malaga, Avda. Carlos Haya s/n; 29010 Malaga, Spain.